7.3 Chronic GVHD: Systemic, Steroid-Sparing & Multidisciplinary Therapy

Chronic GVHD Management: Systemic Therapies, Belumosudil & Multidisciplinary Care

Quick Clinical Summary: Management combines organ-directed care, rehabilitation and systemic therapy when disease severity or progression warrants it. Corticosteroids remain a common initial systemic treatment, but toxicity, incomplete response and dependency drive steroid-sparing choices. Current FDA-approved options in defined previously treated settings include ibrutinib, ruxolitinib, belumosudil and axatilimab-csfr. Extracorporeal photopheresis, other agents and clinical trials are selected by active organ biology, fixed damage, prior therapy, cytopenias, infection, interactions, access and patient goals; established fibrosis is not guaranteed to reverse.

1. Initial Systemic and Supportive Therapy

Systemic corticosteroids remain common initial therapy for moderate/severe or high-risk active chronic GVHD, sometimes with continuation or addition of another immunosuppressant. Starting dose and route depend on organ threat, severity, infection, comorbidity and protocol. Reassess whether findings represent active inflammation, infection, drug toxicity, malignancy or irreversible damage before escalating. Taper from objective response and toxicity; a fixed 12–24-month taper is not universal.

Select PJP, viral, bacterial and mold prophylaxis from steroid dose/duration, other immunosuppression, prior infection, organ function, functional asplenia and local guidance. Bone, glucose, blood pressure, mood, muscle and gastric-risk support is individualized. Do not convert one TMP-SMX, penicillin, antiviral or calcium dose into mandatory therapy for every patient.

2. Recognizing Inadequate Response or Steroid Intolerance

Clinical trials and programs use related but nonidentical definitions. Objective progression during an adequate corticosteroid trial, failure to improve after a clinically appropriate interval, recurrent disease during taper, inability to reduce a toxic steroid exposure, or serious steroid adverse effects should prompt reassessment. Confirm adherence, infection and alternative diagnoses; separate active inflammation from fixed sclerosis or organ damage; then choose a steroid-sparing therapy and a safe taper plan. Do not use one “two-week,” prednisone-dose, or failed-taper formula as a universal bedside trigger.

Document baseline NIH organ scores and patient-reported function before changing therapy, then use the same measures to judge response. Urgent organ-threatening progression may require action before a routine response milestone.

3. FDA-Approved Therapies in Previously Treated cGVHD

Confirm the current U.S. label because indications and formulations evolve:

• Ibrutinib (BTK/ITK inhibitor): approved after failure of at least one systemic line in label-defined adults and pediatric patients. Monitor bleeding, infection, cytopenia, hypertension, arrhythmia and interactions; peri-procedure holding is procedure/risk-specific.
• Ruxolitinib (JAK1/JAK2 inhibitor): approved after failure of one or two systemic lines in adults and patients age 12 years or older. The common labeled dose is 10 mg twice daily with adjustments for cytopenia, organ function and interacting drugs. Monitor counts, infection/reactivation and lipids as labeled; no universal weekly viral-PCR panel applies.
• Belumosudil (ROCK2 inhibitor): approved for adults and pediatric patients age 12 years or older after failure of at least two prior systemic lines. Standard dose is 200 mg daily with food; strong CYP3A inducers and proton-pump inhibitors change dosing per label. Monitor liver tests, infection and other adverse reactions.
• Axatilimab-csfr (Niktimvo; CSF-1 receptor-blocking antibody): FDA-approved after failure of at least two prior systemic lines in adults and pediatric patients weighing at least 40 kg. It is weight-based IV therapy with label-specific infusion, premedication, liver/pancreatic enzyme, infection and infusion-reaction precautions.

Drug choice is not made from organ phenotype alone. Integrate prior therapy, active versus fixed damage, counts, infection, organ function, interactions, access, patient priorities and evidence.

4. Extracorporeal Photopheresis and Other Options

ECP collects mononuclear cells, exposes them ex vivo to 8-methoxypsoralen and UVA, and reinfuses them. Apoptotic-cell processing can promote tolerogenic immune effects. It is used particularly for selected skin, oral and fascial disease and can reduce steroid exposure. It is less broadly immunosuppressive than many drugs but does not make infection risk zero; assess vascular access, anticoagulation, volume shifts, photosensitivity precautions, cytopenias and schedule burden. Other systemic agents, local therapies and trials are selected by disease phenotype and prior response.

5. Organ-Directed and Multidisciplinary Care

Use topical oral/skin/genital anti-inflammatory agents only with diagnosis, site-appropriate formulation and infection surveillance. Dry-eye care may include preservative-free lubrication and ophthalmology-directed anti-inflammatory drops, punctal procedures, serum tears or scleral lenses. Genital disease needs gynecology/urology, sexual-health and pelvic-floor input; active inflammation and stenosis may require topical therapy and dilators. Skin/fascial disease requires moisturization, sun protection, wound care and early PT/OT range-of-motion work. BOS requires pulmonary testing, infection exclusion and a specialist inhaled/systemic plan; long-term azithromycin-containing strategies are not automatic.

Rehabilitation can preserve or improve function even when fibrosis is established, though late contracture may be difficult to reverse. Track NIH organ scores, range of motion, PFTs, oral intake, eye symptoms, sexual function, pain, daily activities, infection and quality of life rather than relying only on clinician global impression.

6. Living on Prolonged Corticosteroids

Chronic GVHD therapy frequently means months to years of systemic corticosteroids, and the accumulated toxicity of that exposure causes as much morbidity as the GVHD it treats. Steroid-sparing agents exist largely because of what follows.

Infection risk persists through the taper. Prophylaxis against Pneumocystis jirovecii, herpesviruses, and encapsulated organisms continues while immunosuppression continues, not until the patient feels better, and the decision to stop belongs to the transplant team.

Bone loss is predictable and preventable. Assess vitamin D and calcium intake, arrange bone density monitoring, encourage weight-bearing activity as tolerated, and report new back or hip pain, since vertebral compression fracture and avascular necrosis both occur in this population.

Glucose intolerance is common and may require treatment even in patients without prior diabetes; monitoring is part of the regimen rather than a response to symptoms.

Adrenal insufficiency follows prolonged exposure. After extended therapy the axis may not respond to physiologic stress, so patients need explicit teaching about stress dosing, a medical alert identifier, and instructions never to stop steroids abruptly.

Muscle wasting, mood change, insomnia, cataract, and skin fragility round out the profile and are worth naming to patients in advance, because unexplained symptoms are more distressing than anticipated ones.